Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Cordis Announces Nationwide Recall of Revised Stent Instructions

By Pharmaceutical Processing | May 10, 2004

WARREN, NJ (May 10, 2004) – The Cordis Endovascular division of Cordis Corp., a Johnson & Johnson company, is recalling revised instructions for the Precise RX Nitinol Stent Transhepatic Biliary System, contained in its Medical Device Notification dated March 29, 2004, the company announced on Friday.

Biliary stents are flexible tubular devices used to drain the biliary tract and to keep the bile duct open.

Use of the Precise RX Stent System, which is cleared to treat obstruction of the bile duct due to malignancies, is reported to result in serious problems at times when used in the vascular system, the company said. Such use is outside of the approved indications.

Cordis said it is aware of nine patient injuries due to air embolism, includingseizure and coma, as well as seven incidents of device malfunction in connection with the use of the system outside of its approved indication.

The Class I recall is for the revised use instructions that were not cleared by the FDA and were contained in Cordis’ Medical Device Notification mailed to its endovascular customers on March 29, 2004, the company said. On May 4, Cordis said it sent a follow-up notification to customers describing “severe adverse events” and advising them to limit the use of the device to the FDA-cleared uses only.

The stent’s labeling contains a warning that the safety and effectiveness of the device for use in the vascular system have not been established.

Dr. Dennis Donohoe, worldwide vice president of regulatory and clinical affairs for Cordis Corp., said “We regret our initial communication did not more strongly reinforce against off-label use.”

A Class I recall is the most serious type of recall. It is a situation in which there is a reasonable probability that use of, or exposure to, a violative product will cause serious adverse health consequences.

Related Articles Read More >

kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Disposable syringe and American currency on black background
PBMs increasingly under fire in drug-pricing battle
Johnson & Johnson logo
Timeline: Navigating Johnson & Johnson’s talc lawsuits and their stock performance impact
pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory
5 core trends in drug recalls: An analysis of 2022 and Q1 2023
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE